血清TFPI-2基因甲基化在胃癌诊断中的临床价值

doi:10.3969/j.issn.1673-8640.2014.07.005

检验医学 ›› 2014, Vol. 29 ›› Issue (7): 712-717.DOI: 10.3969/j.issn.1673-8640.2014.07.005

血清TFPI-2基因甲基化在胃癌诊断中的临床价值

朱立岳¹，关明²，康志华²，高建萍³，翁丽贞¹，章励¹，胡雷光¹

1.上海市静安区中心医院/复旦大学华山医院静安分院检验科，上海 200040；
2.复旦大学附属华山医院检验医学科，上海 200040；
3.上海市静安区中心医院复旦大学华山医院静安分院消化科，上海 200040

收稿日期:2014-02-18 出版日期:2014-07-30 发布日期:2014-07-21
通讯作者: 胡雷光，联系电话:021-62893581。
作者简介:朱立岳，男，1979年生，学士，主管技师，主要从事生物化学及分子生物学检验。
基金资助:
上海市静安区卫生系统“十、百、千”人才建设工程,专业技术骨干培养资助项目(201006B002)

Clinical significance on the detection of serum methylated tissue factor pathway inhibitor 2 gene in the diagnosis of gastric cancer

ZHU Liyue¹,GUAN Ming²,KANG Zhihua²,GAO Jianping³,WENG Lizhen¹,ZHANG Li¹,HU Leiguang¹

1.Department of Clinical Laboratory, Shanghai Jing′ an District Central Hospital/Jing′ an Branch of Huashan Hospital, Fudan University, Shanghai 200040, China;
2. Department of Laboratory Medicine, Huashan Hospital, Fudan University, Shanghai 200040, China;
3.Department of Digestion, Shanghai Jing′ an District Central Hospital/Jing′ an Branch of Huashan Hospital, Fudan University, Shanghai 200040, China

Received:2014-02-18 Online:2014-07-30 Published:2014-07-21

摘要/Abstract

摘要：

目的　通过测定组织及血清组织因子途径抑制物2(TFPI-2）基因甲基化，探讨其作为一种肿瘤标志物对胃癌诊断的临床价值。方法　收集32例胃癌、29例萎缩性胃炎作为研究对象，以30例不排除浅表性胃炎的正常对象作为对照。应用甲基化特异性聚合酶链反应(MSP）方法，测定组织及血清TFPI-2基因甲基化状态。应用电化学发光免疫法测定癌胚抗原(CEA）、糖类抗原199(CA199）。结果　组织TFPI-2基因甲基化检出率胃癌组为53.13%、萎缩性胃炎组为37.93%、对照组为3.33%。胃癌组明显高于对照组(P＜0.05）。血清TFPI-2基因甲基化检出率胃癌组为28.13%，萎缩性胃炎组为6.90%，对照组未检出。胃癌组明显高于萎缩性胃炎组(P＜0.05）和对照组(P＜0.05）。血清TFPI-2基因甲基化检测灵敏度为28.13%，特异性为96.61%。血清检出阳性占组织检出阳性的比率为37.93%。胃癌组血清TFPI-2基因甲基化与性别、年龄、Borrmann′s 分期、CEA和CA199检测结果无关(P＞0.05）。胃癌组血清TFPI-2基因甲基化与CEA、CA199阳性检出率分别为28.13%、21.88%、18.75%。联合3项阳性检出率为53.13%，显著高于3项各自单独检测(P＜；0.05）。结论　血清TFPI-2基因甲基化来源于组织，其对胃癌诊断特异性较高，但灵敏度较差。联合检测血清CEA、CA199有利于提高其灵敏度。血清TFPI-2基因甲基化测定对胃癌的诊断有一定价值。

关键词: 组织因子途径抑制物-2基因, 甲基化, 血清游离DNA, 胃癌

Abstract:

Objective　Through the detection of serum and tissue methylated tissue factor pathway inhibitor 2（TFPI-2） gene， to investigate its clinical significance as a tumor marker for the diagnosis of gastric cancer. Methods　A total of 32 gastric cancer patients and 29 atrophic gastritis patients were enrolled， and 32 healthy subjects including superficial gastritis were enrolled as control group. Methylated TFPI-2 gene was detected by methylation-specific polymerase chain reaction（MSP）. Carcinoembryonic antigen（CEA） and carbohydrate antigen 199（CA199） were determined by electrochemiluminescence immunoassay. Results　The positive rates of methylated TFPI-2 gene in tissue were 53.13% in gastric cancer group， 37.93% in atrophic gastritis group and 3.33% in control group. Tissue methylated TFPI-2 gene was significantly higher in gastric cancer group than in control group（P＜0.05）. The positive rates of methylated TFPI-2 gene in serum were 28.13% in gastric cancer group， 6.90% in atrophic gastritis group， but none in control group. Serum methylated TFPI-2 gene was significantly higher in gastric cancer group than in atrophic gastritis group（P＜0.05） and in control group（P＜0.05）. The sensitivity and specificity of serum methylated TFPI-2 gene for the diagnosis of gastric cancer were 28.13% and 96.61%. The 37.93% positive rate was got in serum against tissue. The TFPI-2 gene methylation in serum showed no correlation with sex， age， Borrmann′ s classification， CEA and CA199 in gastric cancer group（P＞0.05）. In gastric cancer group， the positive rates of methylated TFPI-2 gene， CEA and CA199 were 28.13%， 21.88% and 18.75%， respectively. If performing the combined determination of all the 3 parameters， the positive rate was 53.13%， and the positive rate was significantly higher than those of the single determinations（P＜0.05）. Conclusions　The TFPI-2 gene methylation in serum derives from gastric cancer tissues， and it shows high specificity for the diagnosis of gastric cancer， but the sensitivity is relatively low. It can improve the sensitivity if performing the combined determination with CEA and CA199. The detection of serum TFPI-2 gene methylation has certain significance for diagnosing gastric cancer.

Key words: Tissue factor pathway inhibitor 2 gene, Methylation, Serum free DNA, Gastric cancer

中图分类号:

R446.11

朱立岳，关明，康志华，高建萍，翁丽贞，章励，胡雷光. 血清TFPI-2基因甲基化在胃癌诊断中的临床价值[J]. 检验医学, 2014, 29(7): 712-717.

ZHU Liyue,GUAN Ming,KANG Zhihua,GAO Jianping,WENG Lizhen,ZHANG Li,HU Leiguang. Clinical significance on the detection of serum methylated tissue factor pathway inhibitor 2 gene in the diagnosis of gastric cancer[J]. , 2014, 29(7): 712-717.

参考文献

[1] Zou HZ, Yu BM, Wang ZW, et al. Detection of aberrant p16 methylation in the serum of colorectal cancer patients[J]. Clin Cancer Res, 2002, 8(1): 188-191.
[2] Monk D, Wagschal A, Arnaud P, et al. Comparative analysis of human chromosome 7q21 and mouse proximal chromosome 6 reveals a placental-specific imprinted gene, TFPI2/Tfpi2, which requires EHMT2 and EED for allelic-silencing[J]. Genome Res, 2008, 18(8):1270-1281.
[3] Khan S, Coulson JM, Woll PJ. Genetic abnormalities in plasma DNA of patients with lung cancer and other respiratory diseases[J]. Int J Cancer, 2004, 110(6): 891-895.
[4] Jee CD, Kim MA, Jung EJ, et al. Identification of genes epigenetically silenced by CpG methylation in human gastric carcinoma[J]. Eur J Cancer, 2009, 45(7): 1282-1293.
[5] Takada H, Wakabayashi N, Dohi O, et al. Tissue factor pathway inhibitor 2 (TFPI2) is frequently silenced by aberrant promoter hypermethylation in gastric cancer[J]. Cancer Genet Cytogenet, 2010, 197(1): 16-24.
[6] Hibi K, Goto T, Kitamura YH, et al. Methylation of the TFPI2 gene is frequently detected in advanced gastric carcinoma[J]. Anticancer Res, 2010, 30(10): 4131-4133.
[7] Glckner SC, Dhir M, Yi J M, et al. Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer[J]. Cancer Res, 2009, 69(11): 4691-4699.
[8] Qu Y, Dang S, Hou P. Gene methylation in gastric cancer[J]. Clin Chim Acta, 2013, 424:53-65.
[9] Kong D, Ma D, Bai H, et al. Expression and characterization of the first kunitz domain of human tissue factor pathway inhibitor-2[J]. Biochem Biophys Res Commun, 2004, 324(4): 1179-1185.
[10] Takada H, Wakabayashi N, Dohi O, et al. Tissue factor pathway inhibitor 2 (TFPI2) is frequently silenced by aberrant promoter hypermethylation in gastric cancer[J]. Cancer Genet Cytogenet, 2010, 197(1): 16-24.
[11] 冷雪,孙保存,臧凤琳,等. 胃癌中组织因子途径抑制剂2的表达及其与预后和肿瘤血管生成模式的相关性研究[J]. 中国肿瘤临床, 2012, 39(8):433-438.
[12] 马晓杰,李景鹏,赵勇. 血浆中游离核酸: 分子诊断的新靶点[J]. 生命的化学,2006,26(2): 147-149.
[13] 胡影,倪虹. 人体游离循环 DNA 的研究进展[J]. 遗传,2008,30(7): 815-820.
[14] 孙振阳,汤志刚. TFPI-2基因与消化道肿瘤关系的研究进展[J]. 中华肿瘤防治杂志,2008,15(3): 227-230.
[15] 陆俊骏,钱烨,连强.胃癌遗传学及表遗传学研究进展[J]. 中国医药导报,2013,10(19):43-46.
[16] Lo Nigro C, Wang H, McHugh A, et al. Methylated tissue factor pathway inhibitor 2 (TFPI2) DNA in serum is a biomarker of metastatic melanoma[J]. J Invest Dermatol, 2013, 133(5): 1278-1285.

[1]	高锋. 新型肿瘤标志物的临床应用——前景与挑战[J]. 检验医学, 2023, 38(4): 303-306.
[2]	刘瑞丽, 李兰军, 贾旻蕾, 王一惠, 郝维纳. 胃癌组织miR-7-5p、NOVA2表达与患者临床预后的相关性[J]. 检验医学, 2023, 38(4): 325-329.
[3]	郭霜, 刘红莉, 李娅. EB病毒相关胃癌迁移、侵袭相关miRNA和lncRNA研究进展[J]. 检验医学, 2023, 38(10): 987-996.
[4]	王芮, 李朝燕, 赵爱光. 循环肿瘤DNA检测在胃癌诊疗中的应用现状[J]. 检验医学, 2022, 37(9): 877-881.
[5]	聂甜, 冉子涵, 金磊. 白细胞介素基因多态性与胃癌的相关性研究进展[J]. 检验医学, 2022, 37(9): 882-886.
[6]	冀叶, 袁小笋, 张蕾, 马慧利, 董薇, 李长生, 张敬伟, 任中海, 张怡飞. lncRNA SNHG15在胃癌组织中的表达及临床意义[J]. 检验医学, 2022, 37(5): 409-412.
[7]	梁春芳, 朱康宁, 张琦. 血清miR-21、miR-135a对胃癌患者化疗后复发和转移的预测价值[J]. 检验医学, 2022, 37(5): 417-422.
[8]	龚志贇, 江铭磊, 施卫忠, 卢仁泉, 郭林. 粪便SDC2基因甲基化检测在结直肠癌辅助诊断中的价值[J]. 检验医学, 2022, 37(4): 325-329.
[9]	刘凯, 张沛茹, 谢素红, 郭林, 卢仁泉. 结直肠癌患者SorCS1基因启动子甲基化检测的临床价值[J]. 检验医学, 2022, 37(4): 330-335.
[10]	茆政, 钱增堃, 应斐, 王昭俐, 肖群, 崔凡. E-Cad、G-17、HER-2与胃癌术后复发风险的相关性[J]. 检验医学, 2022, 37(1): 41-46.
[11]	熊仲波, 王蕾, 殷蓓琦, 戴悦, 卫晓青, 卢培. SAA、CRP在胃肠道肿瘤病理分期及转移中的临床价值[J]. 检验医学, 2022, 37(1): 51-55.
[12]	刘超群, 韩东, 徐健. 80例胃癌患者腹水常规细胞形态学检查分析[J]. 检验医学, 2021, 36(5): 517-518.
[13]	师越, 董冬. 循环肿瘤DNA在肾细胞癌中的应用研究进展[J]. 检验医学, 2020, 35(9): 952-956.
[14]	杭晨, 黄飚, 彭海霞, 韦欣, 徐伟红, 盛慧明, 李宁丽. TRFIA检测胃蛋白酶原在溃疡型胃癌筛查中的价值[J]. 检验医学, 2020, 35(7): 721-725.
[15]	金姝, 朱琪, 朱元, 袁亚, 蔡骁垚, 张骥, 闫佩毅. 乳腺癌组织及癌旁组织HER2基因CpG岛甲基化水平及其mRNA表达的研究[J]. 检验医学, 2020, 35(5): 481-486.

血清TFPI-2基因甲基化在胃癌诊断中的临床价值

Clinical significance on the detection of serum methylated tissue factor pathway inhibitor 2 gene in the diagnosis of gastric cancer

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics